Hideki Hanaoka

5.0k citations

78 papers · 2.8k indexed · 2 hit papers · h-index 22

Plant Science top 2%
Molecular Biology top 10%
Epidemiology top 5%
Immunology top 5%
Oncology top 5%

Co-authors: Tomohiko Kato Yoshinori Ohsumi Takeshi Noda Satoshi Tabata Shusei Sato Kohki Yoshimoto Yumiko Shirano Daisuke Shibata
Topics: Immunotherapy and Immune Responses (8 papers)Immune Cell Function and Interaction (7 papers)Endometrial and Cervical Cancer Treatments (7 papers)
Cited by: Immunology Plant Science Oncology
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaThe Journal of Immunology
Partner nations: Japan United States United Kingdom

In The Last Decade

Hideki Hanaoka

72 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Leaf Senescence and Starvation-Induced Chlorosis Are Accelerated by the Disruption of an Arabidopsis Autophagy Gene

2002 497 citations Hideki Hanaoka et al. profile →
Processing of ATG8s, Ubiquitin-Like Proteins, and Their Deconjugation by ATG4s Are Essential for Plant Autophagy

2004 484 citations Hideki Hanaoka et al. profile →

Peers

Countries citing papers authored by Hideki Hanaoka

Since Specialization

Citations

This map shows the geographic impact of Hideki Hanaoka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideki Hanaoka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideki Hanaoka more than expected).

Fields of papers citing papers by Hideki Hanaoka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideki Hanaoka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideki Hanaoka. The network helps show where Hideki Hanaoka may publish in the future.

Co-authorship network of co-authors of Hideki Hanaoka

This figure shows the co-authorship network connecting the top 25 collaborators of Hideki Hanaoka. A scholar is included among the top collaborators of Hideki Hanaoka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideki Hanaoka. Hideki Hanaoka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of the efficacy of angiotensin receptor–neprilysin inhibitor in patients with aortic stenosis undergoing transcatheter aortic valve implantation: protocol for a randomised, open-label, controlled study 2025 ·BMJ Open ·Hideki Kitahara,Shinji OKITA,(unknown),(unknown),Hiroki Goto,Hiroaki Yamamoto,(unknown),Kaoru Matsuura,Yosuke Inaba,Hideki Hanaoka,Goro Matsumiya,Yoshio Kobayashi	0
2	Efficacy and safety of a novel pain management device, AT-04, for endometriosis-related pain: study protocol for a phase III randomized controlled trial 2024 ·Reproductive Health ·Hiroshi Ishikawa,Osamu Yoshino,Fuminori Taniguchi,Tasuku Harada,Mikio Momoeda,Yutaka Osuga,(unknown),(unknown),(unknown),Yosuke Inaba,Hideki Hanaoka,Kaori Koga	1
3	Digital cognitive–behavioural therapy application compared with zolpidem for the treatment of insomnia: protocol for an exploratory randomised controlled trial 2024 ·BMJ Open ·Eiji Shimizu,(unknown),Yoshiyuki Hirano,(unknown),(unknown),Hideki Hanaoka	0
4	Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study 2023 ·Annals of the Rheumatic Diseases ·Shunsuke Furuta,Daiki Nakagomi,Y Kobayashi,Masaki Hiraguri,Takao Sugiyama,Koichi Amano,Takeshi Umibe,Hajime Kono,Kazuhiro Kurasawa,Yasuhiko Kita,Ryutaro Matsumura,Yuko Kaneko,(unknown),Keiju Hiromura,Shin‐ichiro Kagami,Yosuke Inaba,Hideki Hanaoka,Kei Ikeda,Hiroshi Nakajima	12
5	Exploratory clinical trial to evaluate the efficacy and safety of transdermal electrical stimulation in patients with central retinal artery occlusion 2023 ·PLoS ONE ·Gen Miura,T. Fujiwara,(unknown),Yoshihito Ozawa,Yuki Shiko,Yohei Kawasaki,(unknown),Tomoaki Tatsumi,Takayuki Baba,Takuji Kurimoto,Sotaro Mori,Makoto Nakamura,Hideki Hanaoka,Shuichi Yamamoto	4
6	Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study 2022 ·BMJ Open ·Noriyuki Okonogi,Hirokazu Usui,Kazutoshi Murata,Makoto Hori,(unknown),T. Fujiwara,Yasuhisa Fujii,(unknown),Yohei Kawasaki,Yoko Hattori,(unknown),(unknown),Masaru Wakatsuki,Sumitaka Hasegawa,Shigeru Yamada,Hideki Hanaoka,Makio Shozu,Hiroshi Tsuji	7
7	Evaluating the efficacy and safety of transdermal electrical stimulation on the visual functions of patients with retinitis pigmentosa: a clinical trial protocol for a prospective, multicentre, randomised, double-masked and sham-controlled design (ePICO trial) 2022 ·BMJ Open ·Gen Miura,Yoshihito Ozawa,Yuki Shiko,Yohei Kawasaki,(unknown),T. Fujiwara,Takayuki Baba,Hideki Hanaoka,Shuichi Yamamoto	3
8	Implementation of a self-sampling HPV test for non-responders to cervical cancer screening in Japan: secondary analysis of the ACCESS trial 2022 ·Scientific Reports ·Misuzu Fujita,Kengo Nagashima,(unknown),(unknown),(unknown),(unknown),Setsuko Yamamoto,Hideki Hanaoka,Makio Shozu,N Tsuruoka,(unknown),Akira Hata	7
9	Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan 2021 ·Clinical Microbiology and Infection ·Takahiro Kageyama,Kei Ikeda,Shigeru Tanaka,Toshibumi Taniguchi,Hidetoshi Igari,Yoshihiro Onouchi,Atsushi Kaneda,Kazuyuki Matsushita,Hideki Hanaoka,Taka‐aki Nakada,Seiji Ohtori,Ichiro Yoshino,Hisahiro Matsubara,Toshinori Nakayama,Koutaro Yokote,Hiroshi Nakajima	91
10	The Curriculum and Syllabus for Training Clinical Data Managers 2020 ·Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics ·Hiroshi Watanabe,Hideo Kusuoka,Takashi Moritoyo,Hideki Hanaoka	0
11	Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial) 2020 ·BMJ Open ·Akira Mitsuhashi,Yohei Kawasaki,Makoto Hori,T. Fujiwara,Hideki Hanaoka,Makio Shozu	27
12	Clinical Trial to Evaluate Safety and Efficacy of Transdermal Electrical Stimulation on Visual Functions of Patients with Retinitis Pigmentosa 2019 ·Scientific Reports ·Gen Miura,Takeshi Sugawara,Yohei Kawasaki,Tomoaki Tatsumi,(unknown),Takayuki Baba,Hideki Hanaoka,Shuichi Yamamoto	19
13	Efficacy of intravenous nicorandil for fractional flow reserve assessment: study protocol for a crossover randomised trial 2016 ·BMJ Open ·Takeshi Nishi,Hideki Kitahara,Yoshihide Fujimoto,Takashi Nakayama,(unknown),Kengo Nagashima,Hideki Hanaoka,Yoshio Kobayashi	3
14	Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study 2015 ·BMJ Open ·Sonoko Misawa,Yasunori Sato,K. Katayama,Hideki Hanaoka,Setsu Sawai,Minako Beppu,Fumio Nomura,Kazumoto Shibuya,Yukari Sekiguchi,Yuta Iwai,Keisuke Watanabe,Hiroshi Amino,Chikako Ohwada,Masahiro Takeuchi,Emiko Sakaida,Chiaki Nakaseko,Satoshi Kuwabara	40
15	Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial) 2015 ·BMJ Open ·(unknown),Hiromichi Hamada,Yasunori Sato,Hiroyuki Suzuki,Yoshihiro Onouchi,Ryota Ebata,Kengo Nagashima,(unknown),Masaru Terai,Hideki Hanaoka,Akira Hata	22
16	A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial 2015 ·Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·Kazumoto Shibuya,Sonoko Misawa,Hideki Kimura,(unknown),Yasunori Sato,Yukari Sekiguchi,Yuta Iwai,Satsuki Mitsuma,Minako Beppu,Keisuke Watanabe,Yumi Fujimaki,Yukiko Tsuji,Toshio Shimizu,Toshiki Mizuno,Masanori Nakagawa,(unknown),Hideki Hanaoka,Satoshi Kuwabara	35
17	OsNIP3;1, a rice boric acid channel, regulates boron distribution and is essential for growth under boron‐deficient conditions 2014 ·The Plant Journal ·Hideki Hanaoka,Shimpei Uraguchi,Junpei Takano,M. Tanaka,Toru Fujiwara	78
18	Strategy for treating selective serotonin reuptake inhibitor-resistant social anxiety disorder in the clinical setting: a randomised controlled trial protocol of cognitive behavioural therapy in combination with conventional treatment 2013 ·BMJ Open ·Naoki Yoshinaga,Tomihisa Niitsu,Hideki Hanaoka,Yasunori Sato,(unknown),(unknown),Osamu Kobori,Michiko Nakazato,Akiko Nakagawa,Masaomi Iyo,Eiji Shimizu	14
19	A prioritization analysis of disease association by data-mining of functional annotation of human genes 2011 ·Genomics ·(unknown),Susumu Tanaka,Yumi Yamaguchi‐Kabata,Hideki Hanaoka,Chisato Yamasaki,(unknown),Roberto A. Barrero,Boris Lenhard,Milton W. Datta,Mary Shimoyama,Roger E. Bumgarner,Ranajit Chakraborty,Ian Hopkinson,Libin Jia,(unknown),Charles Auffray,Satoshi Minoshima,Tadashi Imanishi,Takashi Gojobori	8
20	A Phase I-II Study of α-Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured Peripheral Blood Mononuclear Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer 2009 ·The Journal of Immunology ·Shinichiro Motohashi,Kaoru Nagato,Naoki Kunii,Heizaburo Yamamoto,Kazuki Yamasaki,Kohsuke Okita,Hideki Hanaoka,Naomi Shimizu,Makoto Suzuki,Ichiro Yoshino,Masaru Taniguchi,Takehiko Fujisawa,Toshinori Nakayama	174

About Hideki Hanaoka

Hideki Hanaoka is a scholar working on Toxicology, Obstetrics and Gynecology and Oncology, having authored 78 papers that have together received 2.8k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (8 papers), Immune Cell Function and Interaction (7 papers) and Endometrial and Cervical Cancer Treatments (7 papers). The work is most often cited by research in Immunology (626 citations), Plant Science (951 citations) and Oncology (542 citations). Hideki Hanaoka has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Tomohiko Kato, Yoshinori Ohsumi, Takeshi Noda, Satoshi Tabata, Shusei Sato, Kohki Yoshimoto, Yumiko Shirano, Daisuke Shibata, Hiroaki Hayashi and Toshinori Nakayama. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact